Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 3.8% – What’s Next?

Shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) traded down 3.8% during mid-day trading on Wednesday . The company traded as low as $1.23 and last traded at $1.26. 118,229 shares traded hands during trading, a decline of 39% from the average session volume of 194,593 shares. The stock had previously closed at $1.31.

Chemomab Therapeutics Trading Up 22.7 %

The stock’s 50-day moving average is $1.58 and its 200-day moving average is $1.16. The firm has a market capitalization of $17.35 million, a price-to-earnings ratio of -0.98 and a beta of 0.52.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period last year, the business posted ($0.72) EPS. On average, equities research analysts anticipate that Chemomab Therapeutics Ltd. will post -1 EPS for the current fiscal year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).